Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Pharma
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
“What is clear is that we have found a better way to target HER2,” an ASCO-invited expert said, referring to Ziihera as better than Herceptin.
Angus Liu
Jan 6, 2026 3:25pm
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
Verastem nixes KRAS G12C plans in non-small cell lung cancer
Jan 2, 2026 10:10am
Neurocrine's Ingrezza misses in cerebral palsy trial
Dec 23, 2025 10:20am
Keytruda, Padcev keep winning streak in bladder cancer
Dec 17, 2025 9:53am
Lilly shifts oral SERD hopes to its largest oncology trial ever
Dec 12, 2025 11:45am
